Hims & Hers to Report Q4 Earnings Amid Guidance Concerns

Faizan Farooque

Tue, February 24, 2026 at 1:21 AM GMT+9 1 min read

In this article:

HIMS

-1.66%

This article first appeared on GuruFocus.

Hims & Hers Health Inc. (HIMS, Financials) is about to release its fourth-quarter earnings. Investors are trying to figure out if the problems caused by compounded semaglutide products will affect the company’s future projections.The telemedicine firm has done well since there is a lot of demand for weight-loss medications, particularly compounded versions of semaglutide when there aren’t enough branded drugs. But more regulatory scrutiny and changes in the supply chain have made others wonder if that revenue stream will last.In the quarter, analysts are likely to look at things like revenue growth, subscriber patterns, and margin performance. Changes to the 2026 advice might change people’s minds, especially because weight-loss products have been a major source of growth.Investors will also want to see what the firm is doing to diversify beyond GLP-1-related medicines, as well as what is going on with regulations and the availability of supplies.The results report will probably move the stock, as investors assess short-term dangers against long-term growth opportunities in digital health.

Terms and Privacy Policy

Privacy Dashboard

More Info